Status:
RECRUITING
Study and Follow-up of Multiple Endocrine Neoplasia Type 1
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Conditions:
Multiple Endocrine Neoplasia
Eligibility:
All Genders
Brief Summary
Multiple Endocrine Neoplasia type I (MEN1) or Wermer syndrome is an autosomal dominant disease that predisposes patients to the development of endocrine tumours, principally parathyroid, pituitary or ...
Eligibility Criteria
Inclusion
- \- Symptomatic individuals with a confirmed diagnosis of MEN1 and who live in France.
- Patients with the following characteristics will also be included in the cohort:
- At least two of the three cardinal clinical lesions (parathyroid, pancreas, pituitary),
- OR an isolated known lesion of the disease, cardinal or not (parathyroid, pancreas, pituitary, adrenal, thymus, bronchus, tumour of the central nervous system) associated with a mutation of the MEN1 locus on chromosome 11q13,
- OR an isolated lesion, cardinal or not (parathyroid, pancreas, pituitary, adrenal, thymus, bronchus, tumour of the central nervous system) in an individual with a confirmed family history of MEN1.
- asymptomatic patients who carry a characteristic mutation of MEN1. Current knowledge suggests that these patients will develop symptoms during their follow-up.
Exclusion
- patients who present a single-organ genetic endocrine disease associated with another genetic syndrome (familial isolated pituitary adenoma FIPA, familial isolated hyperparathyroidism FIHP)
Key Trial Info
Start Date :
July 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2031
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT03348501
Start Date
July 1 2012
End Date
July 1 2031
Last Update
November 21 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Dijon Bourgogne
Dijon, France, 21079